DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, J. T.
Right arrow Articles by Awasthi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J. T.
Right arrow Articles by Awasthi, S.

Vol. 29, Issue 2, 103-110, February 2001

A Flow Cell Assay for Evaluation of Whole Cell Drug Efflux Kinetics: Analysis of Paclitaxel Efflux in CCRF-CEM Leukemia Cells Overexpressing P-Glycoprotein

James T. Lin, Rashmi Sharma,1 James J. Grady, and Sanjay Awasthi2

Departments of Internal Medicine (J.T.L., R.S., S.A.) and Biostatistics (J.J.G.), University of Texas Medical Branch, Galveston, Texas

P-glycoprotein (Pgp) mediates drug accumulation defects in malignant cells in vitro. It confers resistance to multiple drugs including paclitaxel, an agent useful in treating malignancies including acute leukemia. Pgp-mediated drug resistance appears to be due to primary active drug-transport as well as other effects on membrane permeability, but the relative contribution of each is unclear. Flow cells are useful for differentiating transport-mediated efflux from altered membrane permeability, but their utility is limited to attached cells. We developed a novel flow cell to study drug efflux kinetics in suspension culture cells and examined paclitaxel efflux in resistant CEM/VLB100 leukemia cells, which overexpress Pgp, compared with its sensitive CEM parent line. Paclitaxel efflux from both cell lines was described by bi-exponential kinetics. The predominant initial rapid component increased linearly with paclitaxel concentration, consistent with passive efflux, and was faster in CEM/VLB100 than CEM cells. The slow terminal component of efflux was also more rapid for CEM/VLB100 than CEM, and was saturable (Vmax= 9.1 ± 1.1 versus 3.5 ± 0.3 pmol/min/107 cells, respectively) at a lower paclitaxel concentration than the parental CEM cells (km = 63 ± 46 nM versus 144 ± 56 nM, respectively). In CEM/VLB100 cells, this saturable component was inhibited by verapamil and was temperature-sensitive, consistent with Pgp-mediated transport. Verapamil also inhibited the rapid component of efflux, suggesting additional effects on membrane permeability. Our studies show that the present technique is useful for studying drug transport and that effects of Pgp on membrane permeability contribute significantly to the net drug-accumulation defect.


1 Current address: United States Environmental Protection Agency, Research Triangle Park, NC 27711.

2 Current address: University of Texas Arlington, Department of Chemistry and Biochemistry, P.O. Box 19065, Arlington, TX 76019.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Cancer Res.Home page
S. S. Singhal, J. Singhal, S. Yadav, S. Dwivedi, P. J. Boor, Y. C. Awasthi, and S. Awasthi
Regression of Lung and Colon Cancer Xenografts by Depleting or Inhibiting RLIP76 (Ral-Binding Protein 1)
Cancer Res., May 1, 2007; 67(9): 4382 - 4389.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Stuckler, J. Singhal, S. S. Singhal, S. Yadav, Y. C. Awasthi, and S. Awasthi
RLIP76 Transports Vinorelbine and Mediates Drug Resistance in Non-Small Cell Lung Cancer
Cancer Res., February 1, 2005; 65(3): 991 - 998.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.